IP Library Granted Patent US 8,288,546
Granted Patent B2
US 8,288,546 · App. 12/897,824 · Granted Oct 16, 2012

Substituted piperidine compounds and methods of their use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,288,546
App. No.
12/897,824
Granted
Oct 16, 2012
Kind
B2
Abstract

Novel 3,4-disubstituted-4-aryl-piperidine compounds are disclosed. Pharmaceutical compositions containing the 3,4-disubstituted-4-aryl-piperidine compounds and methods of their pharmaceutical uses are also disclosed. The compounds disclosed are useful, inter alia, as antagonists of opioid receptors.

Claims (35)

1. A compound of formula I:

wherein:

R 1 is H or alkyl;

R 2a is alkyl;

R 2b is H, or alkyl;

R 3 is H, alkyl,-or aralkyl;

R 4 is

H, or

alkyl

R 5 is —CH 2 P(═O)OR 7b OR 7c ;

R 7b , and R 7c are each independently H, or alkyl

m is the integer 0, 1, 2, 3, or 4;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 , wherein R 1 is H.

3. A compound according to claim 1 , wherein R 2a and R 2b are trans to each other.

4. A compound according to claim 1 , of formula II:

5. A compound according to claim 1 , wherein R 2a and R 2b are each methyl.

6. A compound according to claim 1 , of formula III:

wherein:

R 3 is aralkyl.

7. A compound according to claim 1 , wherein R 3 is:

8. A compound according to claim 7 , wherein R 1 is H, R 2a and R 2b are each methyl and are trans to each other, m is the integer 1, R 4 is H, and R 7b , and R 7c are each independently H or methyl.

9. A compound according to claim 5 , wherein R 3 is:

10. A compound according to claim 4 , wherein R 2a and R 2b are each methyl.

11. A compound according to claim 1 , of formula IX:

wherein:

R 3 is H, alkyl, or aralkyl.

12. A compound according to claim 1 , wherein R 4 is H.

13. A compound according to claim 1 , wherein m is the integer 1.

14. A pharmaceutical composition, comprising:

a pharmaceutically acceptable carrier; and

an effective amount of a compound according to claim 1 .

15. A pharmaceutical composition according to claim 14 , further comprising an effective amount of at least one opioid.

16. A pharmaceutical composition according to claim 15 , wherein said opioid is alfentanil, buprenorphine, butorphanol, codeine, dezocine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine (pethidine), methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propiram, propoxyphene, sufentanil, tramadol or mixtures thereof.

17. A pharmaceutical composition comprising the compound ({2S-Benzyl -3-[4-(3-hydroxyphenyl)-3R,4R-dimethylpiperidin-l-yl]-propionylamino }-methyl)-phosphonic acid or a pharmaceutically acceptable salt thereof.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jul 24, 2015
From: ROYAL BANK OF CANADA, AS ADMINISTRATIVE AGENT
To: CALIXA THERAPEUTICS, INC.; ADOLOR CORPORATION; CUBIST PHARMACEUTICALS, INC.
Reel/Frame 036180/0070 →
SECURITY AGREEMENT Recorded Nov 20, 2012
From: CUBIST PHARMACEUTICALS, INC.; ADOLOR CORPORATION; CALIXA THERAPEUTICS, INC.; CUBIST PHARMACEUTICALS HOLDINGS, INC.; CUBIST PHARMACEUTICALS U.S.
To: ROYAL BANK OF CANADA, AS ADMINISTRATIVE AGENT
Reel/Frame 029339/0669 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED ON REEL 025208 FRAME 0568. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 18, 2010
From: BOURDONNEC, BERTRAND LE; DOLLE, ROLAND E.
To: ADOLOR CORPORATION
Reel/Frame 025387/0870 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2010
From: LE BOURDONNEC, BERTRAND; DOLLE, ROLAND E.
To: ADOLOR CORPORATION
Reel/Frame 025208/0568 →